申请人:Kotobuki Pharmaceutical Co. Ltd.
公开号:US06124460A1
公开(公告)日:2000-09-26
New therapeutic agents of isoquinuclidine derivatives are represented by the following formula or its hydrochloride salts. ##STR1## (wherein R.sub.1 is hydrogen, carboxyl group, ethoxycarbonyl group, 4-(ethoxycarbonyl)phenyl group, 4-(carboxy)phenyl group, 2-(carboxy)-thiophene-5-yl group, quinoline-5-yl group, 4-(quinoline-5-yl)phenyl group or 4-(3-oxo-2-azabicyclo[2.2.2]octane-2-yl)-phenyl group; R.sub.2 is hydrogen or allyl group; Both X.sub.1 and X.sub.2 are hydrogen and X.sub.1 and X.sub.2 may form an oxo group; m stands for an integer of 0 to 2.) These compounds, have excellent inhibitory activities against squalene synthase, and are useful as a treatment agent for hypercholesterolemia.
新的异喹啉衍生物的治疗剂代表如下化学式或其盐酸盐。其中,R.sub.1为氢、羧基、乙氧羰基、4-(乙氧羰基)苯基、4-(羧基)苯基、2-(羧基)-噻吩-5-基、喹啉-5-基、4-(喹啉-5-基)苯基或4-(3-氧代-2-氮杂双环[2.2.2]辛烷-2-基)-苯基;R.sub.2为氢或烯丙基;X.sub.1和X.sub.2均为氢,X.sub.1和X.sub.2可形成氧代基;m为0至2之间的整数。这些化合物对齐鲁烯合酶具有出色的抑制活性,可作为高胆固醇血症的治疗剂。